跳至主要内容
临床试验/NCT01379625
NCT01379625已完成2 期

Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

Oregon Health and Science University2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
32
试验地点
2
主要终点
Energy Expenditure

研究概览

简要总结

Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD

详细描述

Recruitment: Patients with a long-chain fatty acid oxidation disorder will be recruited through our clinic, past research participants, a patient support website, and recruitment letters mailed to physicians around the US. We will enroll 16 subjects at OHSU and 16 subjects at the University of Pittsburgh, age 7 to 40, with a disorder in fatty acid oxidation.

Procedures: Subjects will be admitted to the clinical research center for 4 days. They will collect all their urine for 24 hours. Heart function will be measured using ultrasound an electrocardiogram (ECG). The motion of the heart will be measured by magnetic resonance imaging (MRI). For this test, the patient lies in the magnetic field of the MRI machine in the Advanced Imaging Resource Center (AIRC) for about 45 minutes. The amount of muscle and fat in the whole body and inside the liver and muscle will be measured by MRS and by dual X-ray absorptiometry (DEXA). Subjects will walk on a treadmill for about 45 minutes. The amount of Calories they use, their heart rate, and if they burn fat or carbohydrates will be measured. Blood samples will be collected before and after exercise. A meal test will be used to determine how much fat they burn. The subjects will drink a liquid breakfast with a stable isotope labeled fat in the breakfast. Breath and blood samples will be collected before and after the meal. The amount Calories burned by each subject will be measured when they are at rest on a bed by indirect calorimetry. The amount of Calories burned by subjects when they are doing their routine daily activities will be measured at home by doubly labeled water. All of these tests will be done at baseline. Then, subjects will be randomly assigned to consume MCT (current standard of care) or triheptanoin at 20% of their estimated Calorie needs for 4 months. The subject and/or the parent will be taught how to use the supplement oil in their diet for cooking and baking. The subject will be sent home and the oil will be shipped to their home. The study coordinator will call the subject or subject's guardian each week to monitor the subject's diet, potential side effects and assist with diet planning. At the end of 4 months, all of the baseline tests will be repeated.

Triheptanoin is experimental oil. It is a clear, odorless oil that can be mixed with foods and used in cooking. Almost all oils are made from even chains of carbon molecules. Triheptanoin is different because the carbon chains are odd in number. The co-investigator of this study at the University of Pittsburgh, Dr. Jerry Vockely, holds an IND for the prescription, and use of triheptanoin in humans (IND 106011).

Data Analysis: The change in exercise ability, heart function, Calories used and body fat after 4 months will be compared between subjects randomized to MCT versus triheptanoin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
7 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD) deficiency
  • > 7 years
  • Ability to travel to CRC to participate
  • Ability to follow protocol

排除标准

  • Hgb < 10 g/dl
  • Peripheral neuropathy that limits ability to complete treadmill studies
  • Inclusion in another research study that alters macronutrient intake
  • Pregnant females
  • history of myocardial infarction or cardiovascular disease

研究组 & 干预措施

Medium Chain Triglyceride (MCT)

Active Comparator

Subjects randomized to consume 20% of energy from MCT

干预措施: Triheptanoin (Drug)

Triheptanoin

Experimental

Subject randomized to consume 20% of energy from triheptanoin.

干预措施: Triheptanoin (Drug)

结局指标

主要结局

Energy Expenditure

时间窗: change from baseline after 4 months of treatment

Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.

Ejection Fraction

时间窗: 4 months

Change in resting ejection fraction over 4 month treatment period

次要结局

  • Exercise Heart Rate(change from baseline to 4 months of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Melanie B Gillingham

Assistant Professor

Oregon Health and Science University

研究点 (2)

Loading locations...

相似试验

已完成
2 期
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With GlycogenosesTarui DiseaseDebrancher DeficiencyGYG1 DEFICIENCY
NCT03642860Rigshospitalet, Denmark3
进行中(未招募)
1 期
The effect of Triheptanoin on excercise in adults and adolescence with glycogenosesCori Forbe's Disease Also called: glycogen storage disease Type III or debrancher deficiency.Tarui's diseaseAlso called: glycogen storage disease Type VII or phosphofructokinase deficiency.Glycogenin-1 deficiency or glycogen storage disease Type XV.MedDRA version: 20.1Level: PTClassification code 10053241Term: Glycogen storage disease type VIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: PTClassification code 10053250Term: Glycogen storage disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10053255Term: Tarui diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10016983Term: Forbes' diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2017-004153-17-DKCopenhagen Neuromuscular Center20
撤回
3 期
Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation DefectsLong-chain Fatty Acid Transport Deficiency
NCT02201368Maria Luz Couce Pico
已完成
1 期
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult SubjectsHealthy Adult Subjects
NCT04335266Jiangsu HengRui Medicine Co., Ltd.20
已完成
1 期
A Food Effect Study of SHR1459 on Healthy Chinese Adult SubjectsHealthy Adult Subjects
NCT04291846Jiangsu HengRui Medicine Co., Ltd.28